A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE2B STUDY OF USTEKINUMAB, A HUMAN MONOCLONAL ANTIBODY TO IL-12/23P40, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS THROUGH WEEK 36 FROM THE CERTIFI TRIAL

(1) Robarts Res Inst

(2) Centocor R&D

(3) Mt Sinai Med Ctr

(4) U Chicago

(5) Cedars-Sinai Med Ctr

(6) U Hosp Gasthuisberg

(7) U Calgary

(8) U Kentucky Med Ctr

(9) Mt Sinai Hosp

(10) U Hosp Schleswig-Holstein

(11) U California San Diego



This item was part of the Drug therapies in intestinal inflammation session at UEG Week Stockholm 2011

This item can be cited as: Gut 2011; 60 (Suppl 3) A99